Genomic alterations and signaling pathways
non-metastatic HNSCC
Among the 56 patients with contributive DNAseq, 49 (88%) had at least one molecular alteration. Thirty-five patients (62%) had an alteration in Overview of gene alterations in untreated, operable, non-metastatic HNSCC patients (Genomic alterations were observed in the genome integrity signaling pathway in 35 patients (62%). Thirty-three patients (59%) had an alteration in the cell cycle pathway, 15 (27%) in the chromatin organization pathway, 13 (23%) in the senescence pathway, 12 (21%) in the apoptosis and the hippo signaling pathways, nine (16%) in the RTK/RAS and the Wnt signaling pathways, and seven (12%) in the PI3K and transcription factor regulator pathways (Supplementary Fig. 